Tazverik Generic: When Will Generic Tazemetostat Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Tazverik Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? TBD no date yet What opens the door is not settled yet
- Has the FDA approved a generic? Not yet None in the FDA’s records yet
- When does the last patent end? May 2038 27 patents listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
There is no expected month yet for generic tazemetostat hydrobromide. None is for sale yet.
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Tazverik as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Tazverik by the Numbers
- Reason
- Not yet clearNo generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
- How sure
- Not rated Too early to rate.
- Price competition
- None filed yet No filers on record
- Brand sales
- $55M a yearSmaller seller
- FDA approved 2020 January 2020 FDA Orange Book
- Patents listed 27 last runs to May 2038 FDA Orange Book
- Medicare Part D spent $25.1M in 2025, for 219 people CMS Part D Spending by Drug
- Medicaid prescriptions 81 in the last four reported quarters, $1.5M CMS Medicaid drug utilization, to Q1 2026
Tazverik’s Road to a Generic
Tazverik has had the market to itself since the FDA approved it in January 2020 (Epizyme Inc). Its FDA protection (orphan drug) runs to June 2027. Its 27 listed patents run to May 2038.
No generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Tazverik Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Tazverik’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,691,507 | A way of using it (U-2852) | September 2031 | Active |
| 8,765,732 | A way of using it (U-2852, U-2853) | September 2031 | Active |
| 8,895,245 | A way of using it (U-2852) | September 2031 | Active |
| 9,090,562 | The active ingredient; the product’s formulation | September 2031 | Active |
| 9,175,331 | A way of using it (U-2852) | September 2031 | Active |
| 9,333,217 | A way of using it (U-2852) | September 2031 | Active |
| 9,334,527 | A way of using it (U-2852) | September 2031 | Active |
| 9,549,931 | A way of using it (U-2736, U-2853, U-2852) | September 2031 | Active |
| 9,855,275 | A way of using it (U-2736) | September 2031 | Active |
| 9,949,999 | A way of using it (U-2851) | September 2031 | Active |
| 10,155,002 | A way of using it (U-2736) | September 2031 | Active |
| 10,420,775 | A way of using it (U-2736, U-2852, U-2853) | September 2031 | Active |
| 11,052,093 | The active ingredient; the product’s formulation; a way of using it (U-2736, U-2852, U-2853) | September 2031 | Active |
| 12,161,645 | A way of using it (U-2853) | September 2031 | Active |
| 12,168,015 | The active ingredient; the product’s formulation | September 2031 | Active |
| 12,168,016 | A way of using it (U-2736, U-2853) | September 2031 | Active |
| 9,394,283 | The active ingredient; the product’s formulation; a way of using it (U-2852, U-2853) | April 2033 | Active |
| 10,245,269 | A way of using it (U-2737, U-2851, U-2854) | April 2033 | Active |
| 10,821,113 | The active ingredient; the product’s formulation | April 2033 | Active |
| 11,491,163 | A way of using it (U-2852, U-2853, U-2736) | April 2033 | Active |
| 8,410,088 | The active ingredient; the product’s formulation | January 2034 | Active |
| 12,162,865 | A way of using it (U-2736) | June 2034 | Active |
| 9,688,665 | A way of using it (U-2736) | August 2034 | Active |
| 9,889,138 | A way of using it (U-2736, U-2852, U-2853) | October 2035 | Active |
| 10,369,155 | A way of using it (U-2736, U-2853, U-2852) | October 2035 | Active |
| 10,786,511 | The product’s formulation | December 2035 | Active |
| 12,168,014 | A way of using it (U-2736, U-2853, U-2852) | May 2038 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| Orphan drug ODE-299 | Seven years of protection for a use in a rare disease. | January 2027 | Active |
| Orphan drug ODE-314 | Seven years of protection for a use in a rare disease. | June 2027 | Active |
Source: FDA Orange Book, application 211723. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Tazemetostat Hydrobromide
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Tazverik yet.
Approved by the FDA
Not yet. The FDA has not approved a generic tazemetostat hydrobromide. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic tazemetostat hydrobromide for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Tazverik Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Tazverik, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Tazverik
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Tazverik, before manufacturer rebates.
- $4.4M
- January to March 2026, the latest CMS has posted
For 136 people, about $18,879 per prescription fill - $25.1M
- 2025, the whole year
For 219 people, about $18,454 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $4,436,641 | 136 | $18,879.32 |
| 2025 | $25,133,660 | 219 | $18,453.50 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Tazverik only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat certain types of cancer (epithelioid sarcoma or follicular lymphoma). It works by slowing or stopping the growth of cancer cells.
Medicaid Prescriptions by Quarter
81 prescriptions in the four quarters to Q1 2026, $1.5M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 13 | $222,271 |
| Q4 2025 | 14 | $252,038 |
| Q3 2025 | 31 | $563,836 |
| Q2 2025 | 23 | $446,885 |
| Q1 2025 | 29 | $483,965 |
Source: CMS Medicaid State Drug Utilization Data, over Tazverik’s own package codes.
Tazverik Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 200MG BASE | Tablet | Oral | January 2020 | Discontinued reference product |
Source: FDA Orange Book, Epizyme Inc. Listed for sale today by Epizyme, Inc. (FDA NDC Directory).
Tazverik NDC Codes and Packages
Each Tazverik package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 72607-0100-00 | TAZEMETOSTAT HYDROBROMIDE 200 mg/1 tablet, film coated | bottle of 240 tablets | Epizyme, Inc. |
| 72607-0100-00 | TAZEMETOSTAT HYDROBROMIDE 200 mg/1 tablet, film coated | bottle of 240 tablets | Epizyme, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Tazverik’s own FDA approval (NDA 211723) are listed, never a generic. Some codes belong to companies that repackage Tazverik: it is the same medicine in a different package.
What a Generic Tazverik Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Tazverik as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Tazverik”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Tazverik
Is there a generic for Tazverik right now?
No. As of October 9, 2026 no generic tazemetostat hydrobromide is listed for sale in the FDA NDC Directory.
When will Tazverik go generic?
There is no expected month yet. No generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
Will generic tazemetostat hydrobromide be the same as Tazverik?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Tazverik?
Not yet. The FDA Orange Book lists no approved generic version of Tazverik.
When does the Tazverik patent expire?
The FDA Orange Book lists 27 patents for Tazverik; the last runs to May 2038. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (a date that is not known yet) weighs all of that.
Changes to This Projection
- First generic expected a date that is not known yet on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- RydaptMidostaurin2026 to 2027
- VerdesoDesonideNovember 2028
- NoctivaDesmopressin AcetateJune 2030
- AlecensaAlectinib Hydrochloride2032 to 2033
- InpefaSotagliflozinMay 2033
- DhivyCarbidopa and LevodopaMarch 2039
About Tazverik
- Generic name tazemetostat hydrobromide
- How it is taken By mouth
- Company Epizyme Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with T
- Have a question? A pharmacist answers, free. Ask about Tazverik
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.